Published on February 24, 2014 at 8:51 AM
AMSBIO has launched CancerSeq™ - a new range of genetically characterised FFPE tissue samples.
CancerSeq™ samples are prepared from genomic DNA extracted from the FFPE tumour tissues and validated by Next Generation Sequencing using Illumina’s TruSeq Amplicon - Cancer Panel (TSACP).Available as tissue slides and whole blocks, samples are delivered with the mutation and variation data for 48 cancer-related genes including BRAF, KRAS, EGFR, ALK and TP53.
CancerSeq™ tissue samples provide researchers with the perfect medium for applications including validation of cancer marker mutation related drug candidates ; companion diagnostic assay development ; cellular localization of tissue specific mRNA and protein expression ; Comparison of the locations of novel genes in different tissues as well as in situ hybridization, immunohistochemistry, and in situ PCR experiments.
Available from several tumour tissue types, donor clinical history data is provided with each CancerSeq™ sample. In addition - AMSBIO offers custom services to characterise your specimens or selected samples from its biorepository of cancer and normal FFPE blocks.
For further information please visit http://amsbio.com/Tissues-Paraffin-tissue-CancerSeq.aspx or contact AMSBIO now on +44-1235-828200 / +1-949-768-8365 / email firstname.lastname@example.org.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.